Clinical Pharmacokinetics
医薬品安全性学研究室

研究業績

【2019】
Rika Tamura, Nao Watanabe, Saki Nakamura, Naoki Yoshimura Sayaka Ozawa, Keiichi Hirono, Fukiko Ichida, Masato Taguchi. Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children. Eur. J. Clin. Pharmacol., in press.

Nanami Shigetomi, Kenta Kamiya, Toru Takamori, Naoki Yoshimura, Sayaka Ozawa, Keiichi Hirono, Fukiko Ichida, Masato Taguchi. Determination of the Serum Unbound Fraction of Tadalafil in Children with Protein-Losing Enteropathy and Its Specific Binding to Human Serum Proteins in Vitro. Biol. Pharm. Bull.:42, 110-115 (2019).


【2018】
小山真澄，平池巧，松浦佳輔，宇佐美陽平，橋本征也. バイオアベイラビリティの個体差を考慮した母集団薬物動態解析の有用性評価(３). 医療薬学, 44: 607-613 (2018).

宇佐美陽平，平山侑紀，小山真澄，橋本征也. ヒト胎児腎HEK293細胞におけるH⁺/キニジン対向輸送系の基質認識特性. 医療薬学, 44: 526-532 (2018).

Ryutaro Matsui, Ryutaro Hattori, Youhei Usami, Masumi Koyama, Yuki Hirayama, Emi Matsuba, Yukiya Hashimoto. Functional characteristics of a renal H⁺/lipophilic cation antiport system in porcine LLC-PK₁ cells and rats. Drug Metabolism and Pharmacokinetics, 33: 96-102 (2018).


【2017】
Nao Watanabe, Hiroki Higashi, Saki Nakamura, Keiko Nomura, Yuichi Adachi, Masato Taguchi. The possible clinical impact of risperidone on P‐glycoprotein-mediated　transport of tacrolimus: A case report and in vitro study. Biopharm Drug Dispos., 39: 30-37 (2017).

Hiroki Higashi, Nao Watanabe, Rika Tamura, and Masato Taguchi. In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol. Pharm. Bull.. 40: 1314-1319 (2017).


【2016】
松葉映美, 服部龍太郎, 大久保翔梧, 深尾美紀, 橋本征也. バイオアベイラビリティの個体差を考慮した母集団薬物動態解析の有用性の評価, 医療薬学, 42: 408-415 (2016).

松葉映美, 服部龍太郎, 大久保翔梧, 深尾美紀, 橋本征也. バイオアベイラビリティの個体差を考慮した母集団薬物動態解析の有用性の評価(2), 医療薬学, 42: 809-816 (2016).

Sekimoto M, Takamori T, Nakamura S, Taguchi M. In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin. Biol. Pharm. Bull., 39: 1359-1363 (2016).

Nakamura S, Watanabe N, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M. A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter. Drug Metabolism and Pharmacokinetics, 31: 234-241 (2016).


【2015】
Takahiro R, Nakamura S, Kohno H, Yoshimura N, Nakamura T, Ozawa S, Hirono K, Ichida F, Taguchi M . Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: A comparison between Sildenafil N-demethylation and Tadalafil. Biol. Pharm. Bull., 38: 58-65 (2015).

Ishida K, Horie A, Matsuba E, Watanabe Y, Fukao M, Hashimoto Y . Importance of lipophilicity and polar surface area of compounds on the transport activity of intestinal H⁺/tertiary amine antiporter. Jpn. J. Pharm. Health Care Sci., 41: 236-243 (2015).


【2014】
Horie A, Ishida K, Watanabe Y, Shibata K, Hashimoto Y. Membrane transport mechanisms of choline in human intestinal epithelial LS180 cells. Biopharm. Drug Dispos., 35: 532-542 (2014).

Ishida K, Fukao M, Itoh H, Uemura O, Hashimoto Y. Advantages and disadvantages of conditional estimation methods for population pharmacokinetic analysis of mizoribine. Jpn. J. Pharm. Health Care Sci., 40: 643-651 (2014).

Kohno H, Ichida F, Hirono K, Ozawa S, Yoshimura N, Nakamura T, Akita C, Ishida K, Taguchi M. Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. Ther. Drug Monit., 36: 576-583 (2014).

Horie A, Ishida K, Shibata K, Taguchi M, Ozawa A, Hirono K, Ichida F, Hashimoto Y. Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption. Biopharm. Drug Dispos., 35: 145-153 (2014).

Fukao M, Ishida K, Horie A, Taguchi M, Nozawa T, Inoue H, Hashimoto Y. Variability of Bioavailability and Intestinal Absorption Mechanisms of Metoprolol. Drug Metab. Pharmacokinet., 29: 162-167 (2014).

Yamaura S, Fukao M, Ishida K, Taguchi M, Hashimoto Y. Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. Eur. J. Drug Metab. Pharmacokinet., 39: 53-59 (2014).


【2013】
Ishida K, Horie A, Nishimura M, Taguchi M, Fujii N, Nozawa T, Inoue H, Hashimoto Y. Variability of bioavailability and intestinal absorption characteristics of bisoprolol. Drug Metab. Pharmacokinet., 28: 491-496 (2013).

Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, Uemura O, Zhang Z, Unadkat JD, Hashimoto Y. Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab. Pharmacokinet., 28: 75-80 (2013).


【2012】
Ishida K, Motoyama O, Shishido S, Tsuzuki K, Hashimoto Y. Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation. Clin. Exp. Nephrol., 16:799-804 (2012).


【2011】
Ishida K, Okamoto M, Ishibashi M, Hashimoto Y. Population pharmacokinetics of mizoribine in adult recipients of renal transplantation. Clin. Exp. Nephrol., 15: 900-906 (2011).

Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y. Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab. Pharmacokinet., 26: 538-543 (2011).

Horie A, Sakata J, Nishimura M, Ishida K, Taguchi M, Hashimoto Y. Mechanisms for membrane transport of metformin in human intestinal Caco-2 cells. Biopharm. Drug Dispos., 32: 253-260 (2011).

Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T, Akita C, Nakayama T, Saji T, Kato Y, Horiuchi I, Hashimoto Y. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab. Pharmacokinet., 26: 208-287 (2011).

Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T, Yoshimura N, Horiuchi I, Taguchi M, Hashimoto Y. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab. Pharmacokinet., 26: 295-299 (2011).

Ishida K, Kaneda H, Uemura O, Ushijima K, Ohta K, Goto Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Takaai M, Hashimoto Y. Evaluation of limited sampling designs to estimate maximal concentration and area under the curve of mizoribine in pediatric patients with renal disease. Drug Metab. Pharmacokinet., 26: 71-78 (2011).


【2010】
Ishida K, Takaai M, Yotsutani A, Yokota A, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y. Mechanisms responsible for different rates of uptake of mizoribine and ribavirin by human epithelial LS180 cells Jpn. J. Pharm. Health Care Sci., 36: 900-905 (2010).

Utsunomiya Y, Hara Y, Ito H, Okonogi H, Miyazaki Y, Hashimoto Y, Hosoya T. Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome., Int. J. Clin. Pharmacol. Ther., 48: 751-755 (2010).

Masago M, Takaai M, Sakata J, Horie A, Ito T, Ishida K, Taguchi M, Hashimoto Y. Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. Biol. Pharm. Bull., 33: 1407-1412 (2010).

Horiuchi I, Kato Y, Nakamura A, Ishida K, Taguchi M, Hashimoto Y. Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes. Biol. Pharm. Bull., 33: 717-720 (2010).

Takaai M, Sakata J, Ishida K, Taguchi M, Hashimoto Y. Mechanisms for transport of methotrexate across apical and basolateral membranes in human intestinal epithelial Caco-2 cells. Jpn. J. Pharm. Health Care Sci., 36: 63-71 (2010).


【2009】
Fukumori S, Masago M, Ishida K, Kayano Y, Taguchi M, and Hashimoto Y. Temperature-dependent specific transport of levofloxacin in human intestinal epithelial LS180 cells. Biopharm. Drug Dispos., 30: 448-456 (2009).

Horiuchi I, Mori Y, Taguchi M, Ichida F, Miyawaki T, and Hashimoto Y. Mechanisms resonsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. Biopharm. Drug Dispos., 30: 326-333 (2009).

Kayano Y, Horiuchi I, Mori Y, Ishida K, Saito T, Taguchi M, and Hashimoto Y. A simulation study to evaluate limited sampling strategies to estimate area under the curve of drug concentration versus time following repetitive oral dosing: limited sampling model versus naive trapezoidal method. Biol. Pharm. Bull., 32: 1486-1490 (2009).

Hashimoto Y. Limited sampling strategy for patient-oriented clinical pharmacokinetic trial. Drug Metab. Pharmacokinet., 24: 199-200 (2009).

Ishida K, Takaai M, Yotsutani A, Taguchi M, and Hashimoto Y. Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells. Biol. Pharm. Bull., 32: 741-745 (2009).

Ishida K, Taguchi M, Akao T, and Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in β-naphthoflavone-treated Caco-2 cells. Biol. Pharm. Bull., 32: 513-516 (2009).


【2008】
Takaai M, Morishita H, Ishida K, Taguchi M, and Hashimoto Y. Contribution of Na+-independent nucleoside transport to ribavirin uptake in the rat intestine and human epithelial LS180 cells. Eur J Pharmacol., 601: 61-65 (2008).

Fukumori S, Murata T, Takaai M, Tahara K, Taguchi M, and Hashimoto Y. The apical uptake transporter of levofloxacin is distinct from the peptide transporter in human intestinal epithelial Caco-2 cells. Drug Metab Pharmacokinet., 23: 373-378 (2008).

Tahara K, Kagawa Y, Takaai M, Taguchi M, and Hashimoto Y. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK₁ Cells. Drug Metab. Pharmacokinet., 23: 340-346 (2008).

Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, and Hashimoto Y. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol. Pharm. Bull., 31: 1297-1300 (2008).

Horiuchi I, Nozawa T, Fujii N, Inoue H, Honda M, Shimizu T, Taguchi M, and Hashimoto Y. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. Biol. Pharm. Bull., 31: 976-980 (2008).

Takaai M, Kayano Y, Shimizu T, Taguchi M, and Hashimoto Y. Additional notes on clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance. Drug Metab. Pharmacokinet., 23: 128-133 (2008).


【2007】
Sakurai Y, Hirayama M, Hashimoto M, Tanaka T, Hasegawa S, Irie S, Ashida K, Kayano Y, Taguchi M, and Hashimoto Y. Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. Biol. Pharm. Bull., 30: 2238-2243 (2007).

Takaai M, Suzuki H, Ishida K, Tahara K, and Hashimoto Y. Pharmacokinetic analysis of transcellular transport of levofloxacin across LLC-PK₁ and caco-2 cell monolayers. Biol. Pharm. Bull., 30: 2167-2172 (2007).

Ishida K, Kayano Y, Taguchi M, and Hashimoto Y. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance. Biol. Pharm. Bull., 30: 2159-2162 (2007).

Koue. T, Kubo M, Funaki T, Fukuda. T, Azuma. J, Takaai. M, Kayano. Y, and Hashimoto. Y. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Biol. Pharm. Bull., 30: 2154-2158 (2007).

Honda M, Toyoda W, Shimizu T, Horiuchi I, Kayano Y, Taguchi M, Nozawa T, Inoue H, and Hashimoto Y. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese. Drug Metab. Pharmacokinet., 22: 382-386 (2007).

Fukumori S, Murata T, Taguchi M, and Hashimoto Y. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 Cells. Drug Metab. Pharmacokinet., 22: 377-381 (2007).

Ishida K, Honda M, Shimizu T, Taguchi M, and Hashimoto Y. Stereoselective metabolism of carvedilol by the β-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. Biol. Pharm. Bull., 30: 1930-1933 (2007).

Tanabe H, Taira S, Taguchi M, and Hashimoto Y. Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol. Pharm. Bull., 30: 552-555 (2007).


【2006】
Honda M, Itoh H, Suzuki T, and Hashimoto Y. Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Biol. Pharm. Bull., 29: 2460-2464 (2006).

Tahara K, Saigusa K, Kagawa Y, Taguchi M, and Hashimoto Y. Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. Drug Metab. Pharmacokinet., 21: 389-394 (2006).

Taguchi M, Urai M, Taira S, Tanabe H, and Hashimoto Y. Endogenous uremic substances are not involved in the reduced hepatic extraction of metoprolol in bilateral ureter-ligated rats. Drug Metab. Pharmacokinet., 21: 156-164 (2006).

Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, and Hashimoto Y. Multiple regression analysis of pharmacokinetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol. Pharm. Bull., 29: 772-778 (2006).

Ishida K, Takaai M, and Hashimoto Y. Pharmacokinetic analysis of transcellular transport of quinidine across monolayers of human intestinal epithelial Caco-2 cells. Biol. Pharm. Bull., 29:522-6 (2006).

Taguchi M, Fujiki A, Iwamoto J, Inoue H, Tahara K, Saigusa K, Horiuchi I, Oshima Y, and Hashimoto Y. Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol. Pharm. Bull., 29: 517-521 (2006).


【2005】
Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Inoue H. Influence of CYP2D6 genotype on metoprolol plasma concentration and β-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J. Cardiovasc. Pharmacol., 46: 713-720 (2005).

Aiba T, Susa M, Fukumori S, and Hashimoto Y. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1α,25-dihydroxy-vitamin D₃ in human intestinal cell lines, Caco-2 and LS180. Drug Metab. Pharmacokinet., 20: 268-274 (2005).

Higashi T, Urai M, Taguchi M, and Hashimoto Y. Mechanism responsible for the decreased hepatic NADPH generation rate in rats with bilateral ureter ligation-induced renal failure. Biol. Pharm. Bull., 29: 1809-1812 (2005).

Honda M, Nozawa T, Igarashi N, Inoue H, Arakawa R, Ogura Y, Okabe H, Taguchi M. and Hashimoto Y. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol. Pharm. Bull., 28: 1476-1479 (2005).

Taguchi M, Nozawa T, Igawa A, Inoue H, Takesono C, Tahara K., and Hashimoto Y. Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. Biol. Pharm. Bull., 28: 876-881 (2005).

Taguchi M, Hongou K, Yagi S, Miyawaki T, Takizawa M, Aiba T, and Hashimoto Y. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet., 20: 107-112 (2005).

Aiba T, Yoshinaga M, Ishida K, Takehara Y, and Hashimoto Y. Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol. Pharm. Bull., 28: 311-315 (2005).

Aiba T, Ishida K, Yoshinaga M, Okuno M, and Hashimoto Y. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biol. Pharm. Bull., 28: 114-119 (2005).


【2004】
Taguchi M, Nozawa T, Mizumaki K, Inoue H, Tahara K, Takesono C, and Hashimoto Y. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. Biol. Pharm. Bull., 27: 1642-1648 (2004).

Okabe H, Higashi T, Ohta T, and Hashimoto Y. Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation. Biol. Pharm. Bull., 27: 1422-1427 (2004).


【2003】
Okabe H, Hasunuma M, and Hashimoto Y. The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm. Res., 20: 1591-1594 (2003).

Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, and Hashimoto Y. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur. J. Clin. Pharmacol., 59: 385-388 (2003).

Okabe H, Mizukami A, Taguchi M, Aiba T, Yasuhara M, and Hashimoto Y. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J. Pharm. Pharmacol., 55: 479-486 (2003).

Aiba T, Takehara Y, Okuno M, and Hashimoto Y. Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm. Res., 20: 745-748 (2003).


【2002】
Shiiki T, Hashimoto Y, and Inui K. Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders. Pharm. Res., 19: 909-913 (2002).

Okabe H, Yano I, Hashimoto Y, Saito H, and Inui K. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol., 54: 65-70 (2002).


【2001】
Hashimoto Y, Aiba T, Yasuhara M, and Hori R. Effect of experimental renal dysfunction on bioavailability of ajmaline in rats. J. Pharm. Pharmacol., 53: 805-813 (2001).


【2000】
Okabe H, Hashimoto Y, and Inui K. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol., 52: 1467-1472 (2000).